Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

QTTB Q32 Bio Inc.

Price (delayed)

$1.84

Market cap

$22.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.89

Enterprise value

-$25.52M

homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.

Highlights
Q32 Bio's revenue has soared by 100% YoY
Q32 Bio's gross profit has surged by 100% YoY
QTTB's quick ratio is up by 10% year-on-year but it is down by 4.8% since the previous quarter
QTTB's equity has dropped by 171% since the previous quarter and by 108% year-on-year
QTTB's net income is down by 30% year-on-year and by 25% since the previous quarter

Key stats

What are the main financial stats of QTTB
Market
Shares outstanding
12.2M
Market cap
$22.44M
Enterprise value
-$25.52M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$63.49M
Net income
-$59.79M
EBIT
-$59.77M
EBITDA
-$58.7M
Free cash flow
-$65.72M
Per share
EPS
-$4.89
EPS diluted
-$4.76
Free cash flow per share
-$5.39
Book value per share
-$0.33
Revenue per share
$0
TBVPS
$6.48
Balance sheet
Total assets
$79.07M
Total liabilities
$83.09M
Debt
$18.17M
Equity
-$4.01M
Working capital
$54.05M
Liquidity
Debt to equity
-4.53
Current ratio
4.71
Quick ratio
4.54
Net debt/EBITDA
0.82
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-59.8%
Return on equity
-447.3%
Return on invested capital
-306.1%
Return on capital employed
-92.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

QTTB stock price

How has the Q32 Bio stock price performed over time
Intraday
-4.66%
1 week
-2.65%
1 month
17.95%
1 year
-92.33%
YTD
-46.51%
QTD
11.52%

Financial performance

How have Q32 Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$63.49M
Net income
-$59.79M
Gross margin
N/A
Net margin
N/A

QTTB financials

Q32 Bio's revenue has soared by 100% YoY
Q32 Bio's gross profit has surged by 100% YoY
QTTB's net income is down by 30% year-on-year and by 25% since the previous quarter
The operating income has declined by 14% year-on-year but it is up by 4% since the previous quarter

Price vs fundamentals

How does QTTB's price correlate with its fundamentals

QTTB Price vs fundamentals

QTTB Earnings waterfall

QTTB Price vs fair value

Growth

What is Q32 Bio's growth rate over time

QTTB growth chart

Valuation

What is Q32 Bio stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A

Valuation vs average

Price to earnings (P/E)

QTTB's EPS has soared by 96% YoY and by 4.5% from the previous quarter

Price to book (P/B)

QTTB's equity has dropped by 171% since the previous quarter and by 108% year-on-year

Price to sales (P/S)

Q32 Bio's revenue has soared by 100% YoY

Efficiency

How efficient is Q32 Bio business performance
The return on equity has dropped by 149% since the previous quarter and by 79% year-on-year
The ROA has plunged by 66% YoY and by 48% from the previous quarter
Q32 Bio's return on invested capital has decreased by 34% QoQ

Dividends

What is QTTB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for QTTB.

Financial health

How did Q32 Bio financials performed over time

Assets vs liabilities

The total assets is 4.8% smaller than the total liabilities
The total assets has declined by 48% year-on-year and by 14% since the previous quarter
The total liabilities has contracted by 20% YoY and by 4.1% from the previous quarter

Debt vs equity

QTTB's equity has dropped by 171% since the previous quarter and by 108% year-on-year
QTTB's debt is down by 2.3% year-on-year

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.